['multiple myeloma']
['lenalidomide', 'dexamethasone']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly diagnosed with symptomatic Multiple Myeloma (MM)

          -  Have not received any prior systemic anti-myeloma therapy

          -  Have measurable disease

          -  Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because
             of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy
             with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old.
             There must be a comorbidity that prevents SCT for a subject < 65 years old

        Exclusion Criteria:

          -  Non-secretory myeloma

          -  Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions

          -  Monoclonal Gammopathy of Undetermined Significance (MGUS)

          -  Active plasma cell leukemia

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
      